Boston Scientific has received FDA approval for its latest generation of defibrillators and heart failure devices. The newly approved devices include the Dynagen Mini and Inogen Mini ICDs, as well as the Dynagen X4 and Inogen X4 CRT-Ds.
According to a company release, the X4 line of quadripolar CRT-Ds offers 70% more pacing options to address high capture thresholds and phrenic nerve stimulation effectively, along with the largest battery capacity in the industry.
The Mini family of ICD’s are up to 20% smaller by volume and up to 24% thinner than competitive devices from other manufacturers, the press release states.
“The tiny size of the Mini ICD provides a real benefit to some patients, in particular those with a smaller frame,” says Hans-Joachim Trappe, University Marien Hospital Herne, Hospital of Ruhr-University, Bochum, Germany. “The Mini ICD not only improves patient comfort, but also provides these patients with innovative technology to help treat life-threatening arrhythmias of the heart.”